EP Patent

EP3052628A1 — Compositions and methods for inhibiting expression of the alas1 gene

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2016-08-10 · 10y expired

What this patent protects

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Drugs covered by this patent

Patent Metadata

Patent number
EP3052628A1
Jurisdiction
EP
Classification
—
Expires
2016-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Icahn School of Medicine at Mount Sinai
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.